ASCO Annual Meeting 2027: What to Expect From Oncology's Biggest Stage

What this article covers
- What This Article Covers
- The American Society of Clinical Oncology (ASCO) will hold its 2027 Annual Meeting at McCormick Place Convention Center in Chicago, Illinois, running June 4 through June 8, 2027. This preview looks at what the meeting is, why it matters to anyone following cancer immunotherapy and cell-based cancer treatment, and what kinds of research tend to surface there based on recent years' programming.
- What the ASCO Annual Meeting Is
- S. professional organization for clinical oncologists, and its Annual Meeting is widely regarded as one of the largest and most influential gatherings in cancer medicine.
- Why This Meeting Matters for Immunotherapy and Cell Therapy
- Although ASCO is a general oncology meeting rather than an immunotherapy-specific congress, recent editions have featured a substantial amount of programming on checkpoint inhibitors, CAR T-cell therapy, bispecific antibodies, antibody-drug conjugates (ADCs), and therapeutic cancer vaccines. At the 2026 meeting, for example, leadership from the Parker Institute for Cancer Immunotherapy highlighted cell-based therapies, in vivo cell engineering, and combination immunotherapy strategies as major talking points, alongside continued momentum for ADCs and precision biomarker tools.
- What's Likely on the Agenda
- Based on the structure of recent ASCO Annual Meetings, attendees can generally expect:
- Who Attends and Why It Matters
- The meeting draws practicing oncologists, academic researchers, pharmaceutical and biotech companies, patient advocacy groups, and health journalists. For patients and caregivers researching emerging cancer therapies, ASCO coverage is often one of the fastest ways that new trial data — including data on cell and immune-based therapies — reaches public reporting, well before formal journal publication in some cases.
What This Article Covers
The American Society of Clinical Oncology (ASCO) will hold its 2027 Annual Meeting at McCormick Place Convention Center in Chicago, Illinois, running June 4 through June 8, 2027. This preview looks at what the meeting is, why it matters to anyone following cancer immunotherapy and cell-based cancer treatment, and what kinds of research tend to surface there based on recent years' programming.
What the ASCO Annual Meeting Is
ASCO is the leading U.S. professional organization for clinical oncologists, and its Annual Meeting is widely regarded as one of the largest and most influential gatherings in cancer medicine. Tens of thousands of oncologists, researchers, patient advocates, industry representatives, and journalists from around the world typically attend. The meeting is also where many practice-changing clinical trial results are presented for the first time, making it a closely watched event for anyone tracking the pace of progress in oncology.
Why This Meeting Matters for Immunotherapy and Cell Therapy
Although ASCO is a general oncology meeting rather than an immunotherapy-specific congress, recent editions have featured a substantial amount of programming on checkpoint inhibitors, CAR T-cell therapy, bispecific antibodies, antibody-drug conjugates (ADCs), and therapeutic cancer vaccines. At the 2026 meeting, for example, leadership from the Parker Institute for Cancer Immunotherapy highlighted cell-based therapies, in vivo cell engineering, and combination immunotherapy strategies as major talking points, alongside continued momentum for ADCs and precision biomarker tools. Given this trajectory, the 2027 meeting is reasonably expected to carry forward significant immuno-oncology content, though ASCO has not yet published its 2027 abstract titles or program theme.
What's Likely on the Agenda
Based on the structure of recent ASCO Annual Meetings, attendees can generally expect:
- Plenary and late-breaking abstract sessions featuring major randomized trial results
- Disease-specific tracks spanning solid tumors and hematologic malignancies
- Dedicated sessions on cellular therapies, immunotherapy combinations, and biomarker-driven patient selection
- Educational sessions aimed at translating research into clinical practice
- A large exhibit hall and industry-sponsored symposia
The specific scientific program and keynote themes for 2027 had not yet been published as of this writing, and readers should check ASCO's official site closer to the meeting for confirmed session listings.
Who Attends and Why It Matters
The meeting draws practicing oncologists, academic researchers, pharmaceutical and biotech companies, patient advocacy groups, and health journalists. For patients and caregivers researching emerging cancer therapies, ASCO coverage is often one of the fastest ways that new trial data — including data on cell and immune-based therapies — reaches public reporting, well before formal journal publication in some cases.
How to Follow the Research Afterward
ASCO typically makes abstracts available through its meeting library and publishes select presentations in its affiliated journals. Medical and trade press, including outlets covering oncology and biotech, generally publish summaries of key presentations within days of each session.
Bottom Line
The 2027 ASCO Annual Meeting is confirmed to take place June 4–8, 2027, at McCormick Place in Chicago, continuing ASCO's role as one of oncology's largest and most closely watched scientific gatherings. While the full 2027 scientific program has not yet been released, recent years' emphasis on cell therapy, immunotherapy combinations, and antibody-drug conjugates suggests this area will again be well represented. As with any major conference, readers should treat meeting presentations as research findings — often early-stage or interim — rather than as approved treatments, and should look for peer-reviewed publication and regulatory review before drawing firm conclusions about any specific therapy discussed there.
Key Questions Answered
- When and where is the ASCO 2027 Annual Meeting?
- It is scheduled for June 4–8, 2027, at McCormick Place Convention Center in Chicago, Illinois.
- Has the 2027 scientific program been released?
- Not as of this writing. ASCO had not yet published 2027 abstract titles or a program theme, so readers should check ASCO's official site closer to the meeting.
- How should readers interpret results presented at ASCO?
- As research findings that are often early-stage or interim, not approved treatments. Look for peer-reviewed publication and regulatory review before drawing firm conclusions.
Sources
- 2027 American Society of Clinical Oncology (ASCO) Annual Meeting, UroToday, 2026, https://www.urotoday.com/calendar-events/2027-american-society-of-clinical-oncology-asco-annual-meeting.html
- ASCO Annual Meeting 2027, ShowsBee Industry News, 2026, https://www.showsbee.com/fairs/97297-ASCO-Annual-Meeting-2027.html
- ASCO 2027 Industry Expert Theater Program, J. Spargo & Associates (official ASCO exhibits/events contractor), 2026, https://events.jspargo.com/ASCO27/CUSTOM/PDF27/ASCO2027IET.pdf
- ASCO Kickoff: Cancer Vaccines, Cell Therapies, and AI-Driven Precision Oncology Signal the Next Era of Immunotherapy, Pharmacy Times, 2026, https://www.pharmacytimes.com/view/asco-kickoff-cancer-vaccines-cell-therapies-and-ai-driven-precision-oncology-signal-the-next-era-of-immunotherapy
- ASCO Annual Meeting resource overview, Sermo, 2026, https://www.sermo.com/resources/asco-annual-meeting
Related Articles
- Research & Industry
AACR IO 2027: What to Expect From the Immuno-Oncology Conference Coming to Los Angeles
AACR IO 2027 meets in Los Angeles February 28–March 3, focusing on cancer vaccines, engineered T cells and early clinical data—not confirmed treatment advances.
- Research & Industry
CAR-T Therapy for Autoimmune Disease in France: What's Actually Happening
France hosts investigational CAR-T trials for severe lupus, but September 2026 safety pauses underscore serious risks and the absence of an approved autoimmune therapy.
- Research & Industry
2027 ASCO Genitourinary Cancers Symposium: What's Coming to San Francisco
A preview of ASCO GU 2027 in San Francisco: dates, sponsors, immunotherapy research trends and why conference findings aren't treatment approvals.